AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

30 September 2016 - Breakthrough therapy designation granted based on Phase 2 clinical data for genotype 1 patients who failed previous ...

Read more →

NICE says yes to another hepatitis C drug

23 September 2016 - A new drug which effectively treats more genotypes of hepatitis C has been recommended for use in ...

Read more →

More options to be made available to treat hepatitis C

9 September 2016 - Another ‘potential curative’ drug for people with chronic hepatitis C will be made available on the NHS. ...

Read more →

TGA approves Zepatier

31 August 2016 - The TGA has approved MSD's Zepatier (grazoprevir with elbasvir). ...

Read more →

New FDA documents reveal history of breakthrough therapy designation for Epclusa

5 August 2016 - Sofosbuvir with velpatasvir was originally granted fast track designation by the FDA on 30 September 2013 ...

Read more →

A pill too hard to swallow: how the NHS is limiting access to high priced drugs

27 July 2016 - A joint investigation by The BMJ and Cambridge and Bath universities uncovers how NHS England tried to ...

Read more →

High cost of new drugs

27 July 2016 - Why government must negotiate a better deal for publicly funded research. ...

Read more →

Hollow victories and hepatitis C

28 July 2016 - When Gilead Sciences introduced sofosbuvir based antivirals in 2014, the drugs were touted as a breakthrough for ...

Read more →

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

27 July 2016 - Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and ...

Read more →

NHS 'abandoning' thousands by rationing hepatitis C drugs

28 July 2016 - Addaction says NHS England decision to treat just 10,000 people a year with costly drugs is ‘potential ...

Read more →

EMA publishes EPAR for Zepatier (grazoprevir with elbasvir)

28 July 2016 - The EMA has published an EPAR for Merck's Zepatier. ...

Read more →

EMA publishes EPAR for Epclusa (sofosbuvir with velpatasvir)

28 July 2016 - The EMA has published an EPAR for Gilead's Epclusa. ...

Read more →

CADTH recommends reimbursement of Sunvepra

20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada. ...

Read more →

AbbVie receives U.S. FDA approval of once daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic hepatitis C

25 July 2016 - New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of Viekira ...

Read more →

Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C

14 July 2016 - Two week treatment with Epclusa provides high cure rates for all six hepatitis C genotypes. ...

Read more →